What a Positive p16/Ki-67 Dual Stain Result Means

A positive p16/Ki-67 dual stain result means that at least one cell on your cervical sample is simultaneously producing two proteins that should not appear together in a healthy cell. That co-expression signals cell-cycle disruption driven by a high-risk HPV infection and is used clinically to flag people who are more likely to have or develop precancerous cervical changes. The test does not diagnose cancer on its own, but it helps your clinician decide whether you need a colposcopy or can safely wait and retest later.

Why p16 and Ki-67 Together Is the Key Signal

In normal cervical tissue, p16 and Ki-67 do opposite jobs. p16 is a brake on cell division; when a cell ramps up p16, it stops growing. Ki-67, by contrast, is a marker of active proliferation. A cell that is dividing expresses Ki-67; a cell that has hit the brakes does not. Under ordinary circumstances, a single cell is either growing or stopped, so seeing both proteins at once would be contradictory.

High-risk HPV changes the equation. When HPV’s E7 protein disables the Rb protein, which normally keeps cell division in check, the cell loses its main growth-control switch. The cell responds by flooding itself with p16 in an attempt to compensate, but because Rb is already knocked out, the brake no longer works. The cell keeps dividing anyway, so Ki-67 stays on too.¹ Finding both markers in the same cell is therefore a biological fingerprint of HPV-driven transformation, regardless of what the cell looks like under the microscope.²

This is what makes the dual stain different from older approaches that rely on a pathologist judging cell shape and size. Those morphological calls are subjective and vary between readers. The dual stain converts a judgment call into a more objective question: is there at least one cell that lights up for both markers, yes or no?

How the Test Fits into Screening

The dual stain is not a first-line screening test. You will encounter it only after an earlier step, usually an HPV test, has come back positive. Most people who carry high-risk HPV will never develop precancer; the virus clears on its own in the majority of cases. The challenge is figuring out which HPV-positive individuals actually need closer evaluation. That sorting step is called triage, and the dual stain was designed for it.

In 2024, the American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Consensus Guidelines Committee formally integrated dual-stain testing into its risk-based management framework, allowing it to be used to triage HPV-positive results.³ That means your clinician can now use a positive or negative dual-stain result, alongside your HPV genotype and screening history, to determine whether to send you directly to colposcopy, bring you back in a year, or extend the interval further.

How Accurate Is the Test at Catching Precancer

The practical question for anyone reading a positive result is: how often does a positive dual stain actually correspond to a precancerous lesion? Two large meta-analyses published in 2025 and 2026 converge on similar numbers. For detecting moderate-to-severe precancer (CIN2 or worse) among HPV-positive women, the test’s pooled sensitivity is around 84–85%, with specificity around 63%.⁴ ⁵ For CIN3 or worse, sensitivity climbs to about 86–88%, while specificity settles around 57–61%.

In plain terms: the test catches the large majority of significant precancers, but a positive result does not guarantee that you have one. Roughly a third of people with a positive dual stain will turn out to have no high-grade lesion on biopsy. That is the trade-off built into the test’s design: it is intentionally calibrated to avoid missing true disease, even if that means some people get colposcopies they technically did not need.

When the test was examined specifically in the context of mildly abnormal Pap results (ASC-US or LSIL), sensitivity for CIN2 or worse reached the low-to-mid nineties, with specificity in the range of 68–81% for ASC-US and somewhat lower for LSIL.⁶ The test tends to perform better when the clinical question is sharper: among women already flagged by HPV positivity, it narrows the field effectively.

How the Dual Stain Compares to a Pap

The dual stain and the Pap test are both looking at cervical cells on a slide, but they answer different questions. The Pap asks a pathologist to judge whether cells look abnormal. The dual stain asks whether cells show a specific biochemical signature of HPV-driven disruption. In head-to-head studies, the dual stain consistently matches or beats the Pap on sensitivity while offering better specificity.

In the ATHENA trial sub-study, dual-stain cytology was substantially more sensitive than Pap cytology for triaging HPV-positive women (about 75% versus 52%), with essentially equal specificity.⁷ A separate evaluation comparing the two directly in HPV-positive samples found that Pap cytology with an ASC-US threshold had a sensitivity of 93% for CIN3 or worse but a specificity of only 49%, while the dual stain had a nearly identical sensitivity of 92% but a specificity of 61%.⁸

That higher specificity matters because it translates directly into fewer unnecessary colposcopies. When a meta-analysis compared the dual stain to HPV testing for triaging women with mildly abnormal cytology, the dual stain had far better specificity for detecting CIN2 or worse (73% versus 41%), meaning fewer false alarms and fewer procedures that would ultimately show nothing worrisome.⁹

What a Negative Result Tells You

A negative dual stain in someone who is HPV-positive is among the most reassuring results current cervical screening can provide. In the PALMS longitudinal study, HPV-positive women with a negative dual stain had a baseline risk of precancer (CIN2 or worse) of just 4%, and even after five years of follow-up that risk only reached about 8.5%. Both figures were meaningfully lower than those seen in women with normal Pap cytology, who had a 6.2% baseline risk and a 12.3% five-year risk.¹⁰

In practical terms, women with a negative dual stain did not cross the threshold risk for needing colposcopy for up to five years. This matters for the many HPV-positive individuals who would otherwise face repeated Pap tests or early colposcopy referrals despite having no precancerous changes. A negative dual stain can spare them that cycle of anxiety and procedures.

Reducing Unnecessary Colposcopies

One of the strongest arguments for dual-stain triage is efficiency. In a large organized screening program, dual-stain triage strategies required about a third fewer colposcopies per detection of CIN3 or worse compared with the standard approach of HPV screening followed by Pap cytology.¹¹ Data from the IMPACT trial confirmed this pattern: dual-stain triage led to fewer referrals overall (49% versus 56%) and higher colposcopy efficiency, meaning fewer procedures were needed to find each case of true precancer.²

If you receive a positive result, then, it is worth knowing that the test has already filtered out a significant chunk of people who would have been referred under older triage strategies but do not actually need the procedure. A positive dual stain carries more weight than a mildly abnormal Pap alone.

How the Dual Stain Positivity Rate Tracks with Disease Severity

A useful way to understand what a positive result signals is to look at how positivity rates scale with actual disease. In a large multicenter study in China, dual-stain positivity was about 18% in women with normal histology, climbed to 54% in CIN1 (mild changes), reached 81% in CIN2 (moderate precancer), hit 93% in CIN3 (severe precancer), and was 95% in squamous cell carcinoma.¹² A separate study found that the jump in positivity was sharpest between low-grade lesions (CIN1) and high-grade lesions (CIN2 or worse), with no significant difference between having no lesion and having CIN1.¹³

The takeaway: a positive dual stain in someone who turns out to have only CIN1 or no lesion at all is not unusual, which is why the test alone does not constitute a diagnosis. But the higher the grade of actual disease, the more reliably the test lights up. At the CIN3 and cancer end, it catches nearly everything.

Reproducibility Between Labs and Readers

A triage test is only useful if different technicians in different labs read it consistently. Traditional Pap cytology has well-known interobserver variability: two pathologists looking at the same slide can disagree, sometimes substantially. The dual stain was designed partly to reduce that subjectivity.

Studies examining reproducibility have generally found good-to-substantial agreement. In one evaluation involving multiple readers, the combined agreement statistic (kappa) was 0.71 overall and 0.73 among cytotechnologists, with individual agreement with a reference evaluation ranging from 83% to 91%.¹⁴ A multicenter European study found that after a targeted training session, agreement among labs jumped from about 78% to 90%.¹⁵

There is a notable caveat, though. Reproducibility drops when labs have limited experience with the test. In one study, the kappa value at experienced centers was 0.75 compared to just 0.50 at centers without documented experience.¹⁶ The “inconclusive” category, where readers cannot confidently call the slide positive or negative, was particularly unreliable across all labs. If your result comes back labeled inconclusive, it may warrant a repeat or additional workup rather than being treated as a definitive answer.

Factors That Can Affect the Result

Not every sample produces a readable dual stain. In a study examining what drives inadequate or positive results in a screening population, increasing age, an already-inadequate Pap, negative mRNA HPV results, and low cell counts on the slide were all linked to higher rates of inadequate reports.¹⁷ A positive dual-stain report, meanwhile, tracked closely with having an abnormal Pap result and with confirmed high-grade disease on biopsy. The study also found that HPV 16/18 infection predicted dual-stain positivity specifically when CIN2 or worse was present, reinforcing the biological link between the highest-risk HPV types and the cell-cycle disruption the test detects.

If your sample was called inadequate, the most likely explanation is a technical problem with the slide rather than anything about your health. Your clinician will typically ask you to come back for a repeat collection.

Glandular Abnormalities and Adenocarcinoma

Most discussion of cervical precancer focuses on squamous cell lesions (the type that lines the outer cervix), but adenocarcinoma (arising from glandular cells higher in the cervical canal) is a growing concern. Adenocarcinoma is harder to catch with conventional screening because the abnormal cells are often higher up and less accessible to a Pap spatula.

The dual stain shows promise here as well. In one study of glandular cell abnormalities, the test was positive in about 86% of patients who ultimately had adenocarcinoma in situ or worse, compared to just 8.5% of those with normal or low-grade findings.¹⁸ A dedicated evaluation of the test for cervical adenocarcinoma reported a sensitivity of about 95% when any positive staining was counted, with specificity of 58%. Among younger women (under 40), both sensitivity and specificity improved further, reaching around 91% and 90% respectively.¹⁹

Cost-Effectiveness

Adding a biomarker test to an already complex screening pathway raises the question of whether the additional cost is justified. Several economic analyses have addressed this. A U.S. model found that adding dual-stain reflex testing to co-testing strategies was cost-effective, with an incremental cost of roughly $50–$62 per patient and a cost per quality-adjusted life-year gained of about $20,000–$25,000, well below the commonly used willingness-to-pay thresholds in the U.S. healthcare system.²⁰

In lower-resource settings, the picture can be even more favorable. A Chilean model found that HPV-based screening with dual-stain reflex testing actually saved money overall compared to cytology-only screening, driven by fewer advanced cancers and fewer repeat screening visits. The dual-stain strategy also produced slightly more quality-adjusted life-years than a comparable approach using Pap cytology as the reflex test.²¹ A Colombian analysis found similar results, with the dual-stain strategy reducing unnecessary colposcopies and biopsies enough to generate net savings.²²

AI-Assisted Reading of Dual-Stain Slides

Because the dual stain essentially turns the diagnostic question into “count the cells that light up for both colors,” it is a natural candidate for automation. Several groups have developed deep-learning algorithms to read dual-stain slides by computer rather than by eye.

In one validation using data from the Kaiser Permanente screening program, an automated algorithm achieved an area under the curve of 0.82 for detecting CIN3 or worse. At its optimal cutoff, the algorithm flagged fewer women as positive than manual reading did (42% versus 50%) while maintaining equivalent sensitivity and achieving higher specificity.²³ A newer version of the algorithm demonstrated stability across different slide preparation methods and even transferred to anal cytology samples, achieving comparable sensitivity to manual reading with improved specificity.²⁴

Automation could help address the reproducibility gap between experienced and inexperienced labs. If a computer reads every slide using the same criteria, the variability that currently depends on human training and experience would shrink. This technology is not yet standard in clinical practice, but it is moving in that direction.

The Test Beyond the Cervix

HPV causes cancers in several anatomic sites, and researchers have explored whether the same dual-stain logic applies to anal cancer screening. Anal intraepithelial neoplasia (AIN) is driven by the same HPV types and the same biological mechanism, so in principle the dual stain should work similarly on anal cytology samples.

In practice, the data are more mixed. A meta-analysis of p16/Ki-67 dual staining for detecting AIN found a pooled sensitivity of 63% and specificity of 65%, considerably lower than what the test achieves in cervical screening.²⁵ Individual studies have reported even more variable results: one found only 33% sensitivity for detecting high-grade anal lesions, though with a very small sample.²⁶ The biological rationale is sound, but the anal canal presents different sampling challenges, and the evidence base is far smaller and less mature than for cervical screening. For now, the dual stain in the anal setting is considered a potential adjunct tool rather than a validated triage strategy.

One small study in HIV-positive patients did find that dual-stain expression tracked with lesion severity in anal biopsies: high-grade AIN showed full-thickness staining while low-grade AIN showed only sparse staining.²⁷ That pattern mirrors what is seen in cervical tissue and supports the idea that the underlying biology translates, even if the screening performance does not yet match.